

**AMENDMENTS TO THE CLAIMS:**

Please amend the claims as follows:

1. (Original) A product comprising:
  - a first component which is a scaffold;
  - a second component which is an adjuvant; and
  - a third component which is an antigen.
2. (Original) A product according to claim 1 wherein the second component is a polypeptide which is a ligand for CD21 or a cell surface molecule on B cells or T cells or follicular dendritic or other antigen presenting cells
3. (Previously Presented) A product according to claim 1 wherein the third component is a polypeptide antigen.
4. (Previously Presented) A product according to claim 1 wherein the third component is a non-polypeptide antigen.
5. (Previously Presented) A product according to claim 1 wherein the scaffold and antigen are the same.
6. (Currently Amended) A product according to claim 5 wherein at least one of the scaffold and antigen are a viral coat protein.
7. (Original) A product according to claim 6 wherein the viral coat protein is Hepatitis B surface antigen.
8. (Previously Presented) A product according to claim 1 wherein the scaffold and adjuvant are the same.
9. (Currently Amended) A product according to claim 8 wherein at least one of

the scaffold and adjuvant are C4bp core protein.

10. (Previously Presented) A pharmaceutical composition comprising the product of claim 1 together with a pharmaceutically acceptable carrier or diluent.

11. (Previously Presented) A method of inducing an immune response to an antigen which method comprises administering to a subject an effective amount of a product according to claim 1.

12. (Original) A method of making a product comprising:

a first component which is a polypeptide scaffold;

a second component which is a polypeptide which is a ligand for CD21 or a cell surface molecule on B cells or T cells or follicular dendritic or other antigen presenting cells; and

a third component which is a polypeptide antigen,

the method comprising expressing nucleic acid encoding the three components in the form of a fusion protein, and recovering the product.

13. (Original) A method of making a product comprising:

a first component which is a polypeptide scaffold;

a second component which is a polypeptide which is a ligand for CD21 or a cell surface molecule on B cells or T cells or follicular dendritic or other antigen presenting cells; and

a third component which is a non-polypeptide antigen,

the method comprising expressing nucleic acid encoding the first and second components in the form of a fusion protein, joining said fusion protein to the third

component, and recovering the product.

14. (Previously Presented) The method of claim 12 wherein the nucleic acid is expressed in a prokaryotic host cell.

15. (Original) A method according to claim 14 wherein the fusion protein is recovered in multimeric form.

16. (Original) A method according to claim 15 wherein the recombinant protein is present at least at a concentration of at least 2 mg/l of cell culture.

17. (Previously Presented) A method according to claim 15 wherein the host prokaryotic cell is *E. coli*.

18. (Original) An expression vector comprising a nucleic acid sequence encoding a fusion protein of

a first component which is a polypeptide scaffold;

a second component which is a polypeptide which is a ligand for CD21 or a cell surface molecule on B cells or T cells or follicular dendritic or other antigen presenting cells; and optionally

a third component which is a polypeptide antigen,  
operably linked to a promoter functional in a host cell.

19. (Original) A bacterial host cell transformed with the expression vector of claim 18.

20. (Original) A eukaryotic host cell transformed with the vector of claim 18.

21. (Original) Use of the expression vector of claim 20 in a method of treatment of the human or animal body.